Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 02, 2024

Impact of Clinical Trial Participation vs Standard of Care on Outcomes in Patients With EGFR Wild-Type and ALK-Negative NSCLC

Lung Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Lung Cancer
Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis
Lung Cancer 2024 Mar 13;190(xx)107536, HA Jung, B Park, S Park, JM Sun, SH Lee, J Seok Ahn, MJ Ahn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading